NCT00217178Unknown4 期
Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)
适应症
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 900
- 试验地点
- 2
- 主要终点
- The change over time (annualized progression slope) in the mean maximum IMT (the mean maximum IMT slope) defined as the average of the maximum IMT across the 12 preselected carotid arterial segments.
研究概览
简要总结
Study Objective:
- To evaluate whether combined therapy with folic acid 2.5 mg/day, vitamin B6 50 mg/day and vitamin B12 1000 micrograms/day vs placebo reduces the rate of atherosclerosis progression, as evaluated by quantitative B-mode carotid ultrasound (US).
详细描述
The HART study is designed as a substudy of the Heart Outcomes Prevention Evaluation-2 (HOPE-2)trial which evaluates the effect of combined therapy ? folic acid and vitamin B6 and B12 on clinical events. The study is designed to enrol 900 study participants randomized to homocysteine lowering therapies or placebo. Follow-up will estimate over 5 years. Study participants will undergo yearly carotid B-Mode ultrasound examinations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Women and Men aged ≥ 55 years at high risk for CV events with: (a) Documented (CAD): i) History of prior MI; ii) stable or unstable angina with documented multivessel CAD or strongly positive stress test; iii) Multivessel CAD and PTCA ≥ 6 months prior to randomization; iv) multivessel CABG ≥ 4 years prior to randomization; v) Multivessel CAD on angiography; (b) Documented peripheral vascular disease (PVD): i) Previous limp bypass surgery and/or previous peripheral percutaneous transluminal angioplasty and/or previous limp or foot amputation due to PVD.ii) History of intermittent claudication with ankle/arm blood pressure ratio of ≤ 0.80 or with significant arterial stenosis on angiography; (c) Documented cerebrovascular disease: i) History of previous ischemic stroke; and (d) Diabetes mellitus with ≥ 1 additional major CV risk factor(s). (2) Provision of informed consent.(3) Adequate baseline carotid US examination.
排除标准
- •Current use of folic acid supplements > 200 mg/day.
- •Known previous adverse reactions to folic acid, Vitamin B6 or B
- •Planned cardiac, peripheral or cerebrovascular.
结局指标
主要结局
The change over time (annualized progression slope) in the mean maximum IMT (the mean maximum IMT slope) defined as the average of the maximum IMT across the 12 preselected carotid arterial segments.
次要结局
- The change over time (annualized progression slope) in the single maximum IMT amongst any of the same preselected carotid artery segments, i.e. the hemodynamically most important lesson.
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
3 期
Efficacy Study of Folic Acid Supplementation in Adolescent EpilepticsEpilepsyNCT02318446Maharashtra University of Health Sciences36
已完成
4 期
Folic Acid Supplementation in Eating DisorderEating DisordersNCT01493674Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz24
已完成
2 期
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)Chronic Kidney DiseaseCardiovascular DiseaseDeathNCT00064753National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)4,110
已完成
不适用
VITRO-Trial. B Vitamins and the Secondary Prevention of Venous ThrombosisDeep-Vein ThrombosisPulmonary EmbolismNCT00314990Radboud University Medical Center620
已完成
2 期
Effect of Homocysteine-lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Endothelium-dependent Vasodilatation of Forearm Resistance Vessels in Patients With Coronary Heart DiseaseEndothelial DysfunctionCardiovascular DiseaseNCT00693589Insel Gruppe AG, University Hospital Bern36